Last €114.15 EUR
Change Today -0.65 / -0.57%
Volume 66.1K
As of 6:11 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa (MRK) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - €135.70
52 Week Low
09/12/13 - €110.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERCK KGAA (MRK)

Related News

No related news articles were found.

merck kgaa (MRK) Related Businessweek News

No Related Businessweek News Found

merck kgaa (MRK) Details

Merck KGaA, together with its subsidiaries, discovers, develops, manufactures, and markets products in the pharmaceutical and chemical sectors worldwide. It operates through four divisions: Merck Serono, Consumer Health, Performance Materials, and Merck Millipore. The Merck Serono division provides prescription medicines for the treatment of cancer, multiple sclerosis, infertility, growth disorders, cardiovascular, and metabolic diseases and allergies. The Consumer Health division offers over-the-counter pharmaceuticals for mobility and agility, everyday health protection, women’s and children’s health, and cough and cold under the Bion 3, Nasivin, Femibion, Seven Seas, Sangobion, Cebion, Sedalmerck, and Kytta brand names. The Performance Materials division provides specialty chemicals for use in various end products, such as liquid crystals for displays; LED materials for lighting, and OLED materials for lighting and displays; functional materials for solar panels and energy solutions; pigments, active ingredients, and fillers for cosmetics, food, and pharmaceutical products; and pigments and functional materials for coatings, printing, and plastics. The Merck Millipore division offers tools and laboratory chemicals that are used in the research, pharmaceutical and biotechnology industries, and analytical and clinical laboratories. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

38,154 Employees
Last Reported Date: 02/28/14
Founded in 1668

merck kgaa (MRK) Top Compensated Officers

Chairman of Executive Board
Total Annual Compensation: €5.4M
General Partner, Member of Executive Board an...
Total Annual Compensation: €4.5M
General Partner, Member of Executive Board an...
Total Annual Compensation: €4.5M
General Partner and Member of Executive Board
Total Annual Compensation: €3.7M
Compensation as of Fiscal Year 2013.

merck kgaa (MRK) Key Developments

Merck KGaA Initiates Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

Oncothyreon Inc. announced that Merck KGaA has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). Merck KGaA, Darmstadt, Germany, is developing tecemotide under a license agreement with Oncothyreon. The START2 study is a Phase 3, multicenter, 1:1 randomized, double-blind, placebo-controlled clinical trial designed to assess the efficacy, safety and tolerability of tecemotide in patients suffering from unresectable, locally advanced (Stage IIIA or IIIB) NSCLC who have had a response or stable disease after at least two cycles of platinum-based concurrent chemoradiotherapy (CRT). Concurrent CRT - a combination of chemotherapy and radiotherapy given at the same time - is the current standard of care for most of these patients. The study is expected to recruit approximately 1,000 patients. The primary endpoint is overall survival (OS). Secondary endpoints include time to symptom progression, progression-free survival and time to progression. Merck KGaA, Darmstadt, Germany received Scientific Advice from the European Medicines Agency (EMA) on the program and reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the trial. START2 is based on the outcome of the prior START trial. While the START trial did not meet the primary endpoint of improving OS in the overall patient population, data from an exploratory analysis of a predefined subgroup of patients, who received tecemotide after concurrent CRT, showed that these patients achieved a median OS of 30.8 months versus 20.6 months in patients treated with placebo (n=806; HR: 0.78; 95% CI 0.64-0.95; p=0.016).

Merck KGaA's Spanish Subsidiary Collaborates with Institute of Rare Diseases Research into Cancer Treatment Resistance

Merck KGaA's Spanish Subsidiary and the Institute of Rare Diseases Research (IIER, Spain) are collaborating on a EUR 330,000 research project into cancer drug resistance. In particular the three-year partnership will focus on gaining a deeper understanding of the mechanisms used by cancer cells to evade the immune system and anti-cancer drugs, an understanding which will then form the basis for development of new therapeutic and diagnostics tools. Merck will be contributing EUR 180,000 with the IIER providing the remainder.

Merck KGaA Initiates Phase 1 Dose Escalation Study of TH 302 in Combination with Gemcitabine and Nab Paclitaxel in Pancreatic Cancer

Threshold Pharmaceuticals Inc. announced that Threshold's partner Merck KGaA through its biopharmaceutical division, has initiated a Phase 1 dose escalation study assessing the safety, tolerability and anti-tumor activity of the investigational hypoxia-targeted drug TH-302 in combination with gemcitabine and nab-paclitaxel (Abraxane(r)) in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. Supportive rationale for the study was derived from preclinical animal xenograft models of pancreatic cancer, in which greater anti-tumor activity was associated with the 'triplet' combination (TH-302 plus gemcitabine plus nab-paclitaxel) compared with that of the 'doublet' combination (gemcitabine plus nab-paclitaxel) without apparent increases in hematological toxicity or peripheral neuropathy. The primary objectives of the Phase 1 trial are to evaluate the safety and tolerability of TH-302 in combination with gemcitabine plus nab-paclitaxel in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma, to identify potential dose-limiting toxicities and to determine the maximum tolerated dose and the recommended Phase 2 doses. Secondary objectives include evaluating anti-tumor activity and levels of CA19-9, exploring the effect of the combination on tumor metabolic activity using -fluorodeoxyglucose (FDG) PET scans and investigating pharmacokinetics. The open-label multi-center study is expected to enroll up to 48 patients. MAESTRO is a randomized, placebo-controlled, international, multi-center, double-blind Phase 3 trial of TH-302 plus gemcitabine compared with placebo plus gemcitabine and is expected to enroll 660 patients. The primary efficacy endpoint is overall survival; the secondary endpoints include efficacy measured by progression-free survival, overall response rate and disease control rate, as well as assessments of safety and tolerability, pharmacokinetics and biomarkers. MAESTRO was initiated following a 214-patient randomized controlled Phase 2b trial of TH-302 plus gemcitabine in which the primary endpoint of improving progression-free survival was achieved.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:GR €114.15 EUR -0.65

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Koninklijke DSM NV €49.58 EUR +0.18
Mylan Inc/PA $47.21 USD +0.98
Seiko Epson Corp ¥2,812 JPY -86.00
Sumitomo Chemical Co Ltd ¥385.00 JPY 0.00
Takeda Pharmaceutical Co Ltd ¥4,546 JPY +18.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MRK Industry Range
Price/Earnings 20.6x
Price/Sales 2.2x
Price/Book 2.2x
Price/Cash Flow 3.6x
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at